Olaparib Tablets is the first oral PARP (Poly ADP-ribose polymerase) inhibitor, targeting PARP1, PARP2, and PARP3. It exploits defects in the tumor’s DNA repair pathways to preferentially kill cancer cells. This mechanism enables Olaparib to be especially effective in treating tumors with DNA damage repair deficiencies. Olaparib is mainly used as a first-line or maintenance treatment for ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with BRCA mutations and homologous recombination repair defects (HRD). The trial results show that Olaparib can inhibit the proliferation of tumor cell lines in vitro and suppress the growth of human tumor xenografts in mice in vivo. Both monotherapy and post-platinum chemotherapy treatment are effective.

Zenorn^® Olaparib Tablets were approved for market in August 2024, offering more treatment options for tumor patients. It can be used as a first-line treatment for metastatic colorectal cancer, hepatocellular carcinoma, and advanced or metastatic gastrointestinal stromal tumors.